鸭传染性浆膜炎铝胶疫苗研究

将鸭疫里氏杆菌通过改良酵母肉汤培养，得菌数在500－2000亿／ml的菌液：甲醛灭活，与氢氧化铝液（含量1.4%)2:1混合搅匀，制成铝胶疫苗，经无菌检验，安全检验合格，免疫5日龄雏鸭，分别于7d,10d,20d后攻毒（攻毒剂量：0.25ml），攻毒保护率为50％，50％，75％，5日龄，12日龄两次免疫，10日后攻毒保护率为10％。     

鸭传染性浆膜炎蜂胶疫苗研制

从重庆疫鸭中分离到2株细菌，经细菌形态学、生理生化指标鉴定，证明为鸭疫里氏杆菌（Riemerella anatipestifer,RA)。用改良的血清酵母肉汤进行培菌培养，将2菌株菌液混合（1：1，体积比），经甲醛灭活后加入蜂胶左剂，制成蜂胶灭活疫苗。用其免疫5－7日龄雏鸭，一免后7、10、15d皮下注射RA混合菌液攻毒（0．2mL/只）,平均保护率达66．67％；10d后二免，二免后7、10d攻毒（0．2mL／只）,平均保护率达94．47％。     

鸭传染性浆膜炎疫苗的研究

用从浙江省分离鉴定的鸭疫里氏杆菌RA-J、RA-L菌株研制疫苗,采用改进的液体培养和鸭胚培养工艺,抗原含量分别达120-186亿CFU／ml和280-310CFU／ml,免疫0.5ml/只,2MLD强毒攻击,平均保护率达94.2％（48／52）,免疫后第7天保护率达80％（16／20）,10天达93.8％（15／16）,疫苗在4℃-8℃条件下保存7个半月和1年的保护率达90％和85％。野外扩大试验和临床推广试用236万羽份表明,效果良好。     

鸭传染性浆膜炎免疫研究进展

鸭传染性浆膜炎是由鸭疫里氏杆菌(RA)又名鸭疫巴氏杆菌引起的一种严重危害雏鸭的传染病。本病呈急性败血症或慢性过程，以纤维素性心包炎、肝周炎、气囊炎、脑膜炎和干酪性输卵管炎为特征。1～8周龄雏鸭易感，恶劣环境条件可诱发此病。死亡率最高可达75％。慢性经过的鸭主要表现脑膜炎症状，即斜颈，生长缓慢成僵鸭，给养鸭业造成巨大的损失。　　药物防治是我国目前控制该病的主要措施。虽然药敏试验表明该菌对多种药物敏感，但实际防治效果并不理想；加上肉鸭在养殖全程均对该菌易感，要达到较好的治疗效果，必须反复投药，既增加了成本…     

鸭传染性浆膜炎的诊断

本就一起鸭传染性浆膜炎进行诊断，通过流行病学调查，临床症状，病理变化，细菌学检查总结为急性鸭传染性浆膜炎。     

鸭传染性浆膜炎疫苗的研究进展

鸭传染性浆膜炎是由鸭疫里默氏杆菌(Riemerella anatipestifer,RA)经呼吸道、皮肤等途径感染1-8周龄雏鸭引起的急性或慢性败血性疾病.临床上主要以头颈歪斜、腿翅瘫痪、共济失调、纤维素性心包炎、肝周炎、气囊炎、胸膜炎、结膜炎以及干酪性输卵管炎为特征,死亡率较高,耐过雏鸭生长性能、饲料报酬低下[1].     

鸭传染性浆膜炎的诊疗

１９９７年８月以来,在我市养鸭户中不断发生鸭的以下痢和神经失调为主要症状的急性传染病,经市畜牧兽医技术推广中心兽医门诊及其化验室检验,综合诊断为鸭传染性浆膜炎,其病原为鸭疫巴氏杆菌。１流行情况据中心门诊统计,１９９７年８月至１９９８年１１月,先后在１...     

鸭传染性浆膜炎的疫苗免疫方法

<正>鸭传染性浆膜炎,又称新鸭病、鸭败血症、鸭疫综合征、鸭疫巴氏杆菌病等。是由鸭疫里默氏杆菌引起的雏鸭雏鹅、雏火鸡以及野鸡等多种雏禽的一种急性或慢性的接触传染性疾病。在鸭主要侵害1~8周龄的幼鸭,尤以2~3周龄的雏鸭最易感,发病率常高达90%以上,死亡率达5%~80%不等。临床上主要表现为眼鼻有浆液性分泌物、下痢、共济失调、头颈震颤和昏迷,少数慢性病例出现头颈歪斜等症状;在病变上以     

自家苗治疗连城白鸭浆膜炎的效果研究

选择刚死亡且具有典型鸭传染性浆膜炎病变的病死鸭,无菌采集其肝组织,对疑似鸭疫里默氏杆菌进行分离鉴定,证明确为鸭疫里默氏杆菌,然后将该菌株扩增培养,通过甲醛灭活,再经无菌试验和安全性试验验证,制成安全的自家苗,随后对自家苗作临床效力试验,结果证明该苗具有较好的免疫防治效果,适合在当地推广使用。     

Immunization effectiveness of the inactivated vaccine against infectious bovine rhinotracheitis (IBR) with an oily adjuvant]

The adjuvant vaccine against infectious bovine rhinotracheitis (IBR) was tested as to its innocuousness and immunogenicity. The immunity response induced by a single or double application of different vaccine doses was evaluated according to the content of neutralization antibodies (NP) in the blood serum. A direct dependence was revealed between the size of the inoculum and NP content in the blood serum, with NP titres of 1 : 9.3; 1 : 26.6, 1 : 80 and 1 : 149 after doubled application of 1, 2, 5, and 10 ml of the vaccine. The calves inoculated at an age of one week produced antibodies in the same titres as one- to five-month-old calves. Singly inoculated animals mostly showed zero-level or low antibody titres, but revaccination induced general serum-positivity with NP titres 1 : 4 to 1 : 128. The animals which had been in contact with the IBR virus and were serologically negative during inoculation or had an NP content in the blood serum at a titre of 1 : 4 or less, gave an anamnestic response to inoculation, but revaccination did not lead to a significant rise in antibody content. Double administration of 2 ml of vaccine in four production charges induced the production of antibodies with average titres of 1 : 36, 1 : 25; 1 : 31 and 1 : 24. Inoculation of susceptible animals in non-infected herds and of clinically healthy animals in infected herds did not cause any health disorders. IBR; inactivated adjuvant vaccine; different age; different doses; immunity response; neutralization antibodies.     

沛县鸭传染性浆膜炎的病原分离鉴定及药敏试验

收集沛县具有典型鸭传染性浆膜炎症状的34份病死鸭进行细菌的分离培养。总共得到18株疑似鸭疫里默氏杆菌（RA）,从中随机选取10株RA进行生化鉴定及动物回归试验,经确认后使用本地区常见的抗菌药进行了纸片法药敏试验,结果发现RA分离菌株对头孢噻肟、氧氟沙星、阿莫西林＋棒酸等药物敏感度较好,对氟苯尼考、丁胺卡那、阿奇霉素等药物敏感度很低。研究结果为该地区鸭传染性浆膜炎的药物防治提供了很好的理论依据。     

徐州地区鸭传染性浆膜炎的病原分离鉴定及药敏试验

从徐州地区临床疑似鸭传染性浆膜炎发病鸭中分离到细菌21株，通过细菌形态、培养特怔、生化试验和动物试验，鉴定为鸭疫里默氏杆菌菌株，对不同地区分离到的21株菌进行了24种常用抗菌药物的药敏试验，结果该24个菌株对头孢类药物、红霉素、链霉素、妥布霉素、新霉素、氯霉素、泰乐菌素、痢特灵等几种药物敏感性较高，对喹诺酮类、强力霉素、丁安卡那霉素、林肯霉素、庆大霉素、氟苯尼考、利福平、复方新诺明等均不同程度地产生了耐药性。不同地区分离到的鸭疫里默氏杆菌对不同抗菌药的敏感程度存在较大差异性，研究结果为该地区鸭传染性浆膜炎的药物防治提供了很好的理论依据.     

NDV、IBDV二联灭活苗对蛋雏鸡免疫程序研究

为探讨鸡新城疫病毒(NDV)、传染性法氏囊病毒(IBDV)二联灭活疫苗在蛋雏鸡养殖中的实际应用效果进行本试验。用鸡新城疫、传染性法氏囊二联灭活疫苗及传染性法氏囊活疫苗以不同免疫程序免疫7~14日龄蛋雏鸡,定期监测NDV、IBDV抗体水平,并在雏鸡60日龄时进行攻毒保护试验。结果表明,各二联苗免疫组NDV抗体水平在免疫后14 d即达到NDV血清学最低有效保护价标准,并维持至雏鸡60日龄。免疫后28 d,灭活苗一次性免疫各组IBDV中和抗体水平显著高于活苗两次免疫组,琼扩抗体水平与活苗两次免疫组无明显差异。雏鸡60日龄时攻毒,各免疫组均100%保护,对照组无保护。以上结果说明该二联灭活疫苗可替代IBDV活毒疫苗用于7~14日龄商品雏鸡免疫,免疫期至少为60d。     

鸭浆膜炎、鸭病毒性肝炎二联灭活苗研究

将自然分离的2株鸭疫里默氏杆茵接种适宜培养基,收获茵液用甲醛灭活;用Ⅰ型鸭肝炎病毒(DHV)接种易感鸡胚收获含毒胚组液,经甲醛灭活后与灭活的鸭疫里默氏杆菌液混合,制备3批油乳剂灭活苗,并对其安全性和免疫原性进行测定。3批灭活苗通过接种2周龄雏鸭(0．5mL／只),2周后可测到DHV中和抗体,3周后攻毒保护率达80％以上。鸭疫里默氏杆茵3周后攻毒保护力80％以上。2周龄雏鸭每只皮下注射1ml,观察14d,免疫鸭全部健活,局部无不良反应。     

Protection of chickens against infectious bronchitis virus with a multivalent DNA vaccine and boosting with an inactivated vaccine

The protective efficacy of DNA plasmids encoding avian infectious bronchitis virus (IBV) S1, N, or M protein was investigated in chickens. Chickens were inoculated monovalently (with plasmid pVAX1-16S1, pVAX1-16M, or pVAX1-16N alone) or multivalently (combination of the three different plasmids, pVAX1-16S1/M/N). A prime-boost immunization protocol against IBV was developed. Chickens were immunized with the multivalent DNA vaccine twice and then boosted with an inactivated vaccine once. Antibody titers of the chickens immunized with pVAX1-16S1/M/N were much higher than those of the monovalent groups (p < 0.01). A protective rate up to 90% was observed in the pVAX1-16S1/M/N group. The serum antibody titers in the prime-boost birds were significantly higher than those of the multivalent DNA vaccine group (p < 0.01) but not significantly different compared to the inactivated vaccine group at 49 days of age. Additionally, the prime-boost group also showed the highest level of IBV-specific cellular proliferation compared to the monovalent groups (p < 0.01) but no significant difference was found compared to the multivalent DNA vaccine group, and the prime-boost group completely protected from followed viral challenge.     

Comparison of the immunizing effectiveness of subunit vaccine and inactivated viral oil vaccine against infectious rhinotracheitis of cattle

Trials were conducted on rabbits and cattle to compare the immunizing effectiveness of the subunit vaccine against infectious bovine rhinotracheitis (IBR), representing antigens separated by the solubilization of the IBR virus-infected cells by means of Triton X-100 with oil adjuvant, with the inactivated oil IBR vaccine. The rabbits inoculated and re-vaccinated with both vaccines in an interval of three weeks produced neutralizing antibodies in medium titres, the values of these antibodies were balanced in both groups. Cattle immunized with the subunit vaccine reacted to the inoculation and re-vaccination by producing serum antibodies of higher titres, as compared with the cattle inoculated with the virus vaccine; secretory antibodies were detected only after re-vaccination and had balanced values in both test groups. After intranasal infection with the virulent virus performed after 14 days from re-vaccination, the calves inoculated with the subunit and virus vaccines were protected against clinical disease whereas the non-inoculated control calves fell ill with symptoms characteristic of IBR. The immunized animals of both experimental groups had a smaller amount of virus p.i. in nasal secretions and for a shorter time than the control non-inoculated calves. The intensity of multiplication and persistence of infectious virus excretion were the same in both experimental groups.